{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:44:24Z","timestamp":1793133864318,"version":"4.5.0"},"reference-count":224,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>This review summarizes recent advances in understanding the pathogenesis and therapeutic landscape of juvenile-onset systemic lupus erythematosus (jSLE), with a focus on how emerging genetic and immunologic insights inform patient stratification, targeted treatments, and Treat-to-Target (T2T) approaches in pediatric care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>\n                      Studies of (ultra-)rare gene variants (e.g., affecting\n                      <jats:italic>TLR7<\/jats:italic>\n                      ,\n                      <jats:italic>UNC93B1<\/jats:italic>\n                      ,\n                      <jats:italic>PLD4<\/jats:italic>\n                      ,\n                      <jats:italic>PTPN2<\/jats:italic>\n                      ,\n                      <jats:italic>BACH2<\/jats:italic>\n                      ) aided in understanding key pathogenic pathways, and allowed linking these to associated clinical phenotypes. Multi-ancestral genomic studies and cumulative genetic metrics are refining links between patient ancestry, disease expression, genetic burden and variability, supporting personalized management. The therapeutic armamentarium has expanded with the approval of the first two biologic agents for SLE, belimumab and anifrolumab, alongside emerging molecular therapies such as protein kinase inhibitors (including JAK inhibitors), and new approaches to lupus nephritis induction using multitarget regimens that combine standard therapy with belimumab or calcineurin inhibitors. Early experience with CD19-directed CAR-T cells promises remarkable efficacy with sustained drug-free remission and good short-term safety in refractory SLE, although long-term outcomes remain under evaluation. Pediatric T2T strategies have been adapted to jSLE, and achievement of these targets are associate with improved disease control and reduced long-term damage.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Recent findings confirm that converging genetic variants and immune pathway dysregulation underlie the heterogeneity of jSLE, supporting precision management. Advances in biologic and cellular therapies, together with paediatric T2T strategies, promise to improve outcomes. Future priorities include integrating genomic stratification into clinical practice and conducting dedicated pediatric trials of novel targeted therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11926-025-01207-7","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:26:40Z","timestamp":1766039200000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Juvenile-onset Systemic Lupus Erythematosus: Recent Advances in Pathogenesis and Treatment"],"prefix":"10.1007","volume":"27","author":[{"given":"Valentina","family":"Natoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Charras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve MD","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Hedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"issue":"8","key":"1207_CR1","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/s41590-024-01898-7","volume":"25","author":"GC Tsokos","year":"2024","unstructured":"Tsokos GC. The immunology of systemic lupus erythematosus. Nat Immunol. 2024;25(8):1332\u201343.","journal-title":"Nat Immunol"},{"issue":"10","key":"1207_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41584-024-01152-2","volume":"20","author":"Y Ghodke-Puranik","year":"2024","unstructured":"Ghodke-Puranik Y, Olferiev M, Crow MK. Systemic lupus erythematosus genetics: insights into pathogenesis and implications for therapy. Nat Rev Rheumatol. 2024;20(10):635\u201348.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"1207_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11926-021-00985-0","volume":"23","author":"A Charras","year":"2021","unstructured":"Charras A, Smith E, Hedrich CM. Systemic lupus erythematosus in children and young people. Curr Rheumatol Rep. 2021;23(3):20.","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"1207_CR4","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.berh.2018.02.001","volume":"31","author":"CM Hedrich","year":"2017","unstructured":"Hedrich CM, Smith EMD, Beresford MW. Juvenile-onset systemic lupus erythematosus (jSLE) - pathophysiological concepts and treatment options. Best Pract Res Clin Rheumatol. 2017;31(4):488\u2013504.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"22","key":"1207_CR5","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMra1100359","volume":"365","author":"GC Tsokos","year":"2011","unstructured":"Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110\u201321.","journal-title":"N Engl J Med"},{"issue":"14","key":"1207_CR6","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1177\/0961203316644333","volume":"25","author":"N Ambrose","year":"2016","unstructured":"Ambrose N, et al. Differences in disease phenotype and severity in SLE across age groups. Lupus. 2016;25(14):1542\u201350.","journal-title":"Lupus"},{"key":"1207_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.clim.2018.02.002","volume":"196","author":"CM Hedrich","year":"2018","unstructured":"Hedrich CM. Mechanistic aspects of epigenetic dysregulation in SLE. Clin Immunol. 2018;196:3\u201311.","journal-title":"Clin Immunol"},{"key":"1207_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108907","volume":"234","author":"T Alexander","year":"2022","unstructured":"Alexander T, Hedrich CM.Systemic lupus erythematosus-Are children miniature adults? Clin Immunol. 2022;234:108907.","journal-title":"Clin Immunol"},{"issue":"2","key":"1207_CR9","doi-asserted-by":"publisher","first-page":"e70003","DOI":"10.1002\/acr2.70003","volume":"7","author":"A Belot","year":"2025","unstructured":"Belot A, et al. How (Ultra-)Rare gene variants improve our Understanding of more common autoimmune and inflammatory diseases. ACR Open Rheumatol. 2025;7(2):e70003.","journal-title":"ACR Open Rheumatol"},{"issue":"SI2","key":"1207_CR10","doi-asserted-by":"publisher","first-page":"SI210","DOI":"10.1093\/rheumatology\/keac275","volume":"62","author":"A Charras","year":"2023","unstructured":"Charras A, et al. Panel sequencing links rare, likely damaging gene variants with distinct clinical phenotypes and outcomes in juvenile-onset SLE. Rheumatology (Oxford). 2023;62(SI2):SI210\u201325.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"1207_CR11","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00109-016-1465-5","volume":"94","author":"H Kim","year":"2016","unstructured":"Kim H, Sanchez GA, Goldbach-Mansky R. Insights from Mendelian interferonopathies: comparison of CANDLE, SAVI with AGS, monogenic lupus. J Mol Med (Berl). 2016;94(10):1111\u201327.","journal-title":"J Mol Med (Berl)"},{"issue":"6644","key":"1207_CR12","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1126\/science.adg2992","volume":"380","author":"A Harroud","year":"2023","unstructured":"Harroud A, Hafler DA. Common genetic factors among autoimmune diseases. Science. 2023;380(6644):485\u201390.","journal-title":"Science"},{"issue":"2","key":"1207_CR13","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1016\/S2665-9913(19)30142-0","volume":"2","author":"A Belot","year":"2020","unstructured":"Belot A, et al. Contribution of rare and predicted pathogenic gene variants to childhood-onset lupus: a large, genetic panel analysis of British and French cohorts. Lancet Rheumatol. 2020;2(2):e99\u2013109.","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"1207_CR14","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3899\/jrheum.220513","volume":"50","author":"MC Misztal","year":"2023","unstructured":"Misztal MC, et al. Genome-wide sequencing identified rare genetic variants for childhood-onset monogenic lupus. J Rheumatol. 2023;50(5):671\u20135.","journal-title":"J Rheumatol"},{"issue":"2","key":"1207_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/BOR.0000000000001072","volume":"37","author":"A Charras","year":"2025","unstructured":"Charras A, et al. Genetic and epigenetic factors shape phenotypes and outcomes in systemic lupus erythematosus - focus on juvenile-onset systemic lupus erythematosus. Curr Opin Rheumatol. 2025;37(2):149\u201363.","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"1207_CR16","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1007\/s00296-020-04653-x","volume":"40","author":"B Kara","year":"2020","unstructured":"Kara B, et al. Monogenic lupus due to spondyloenchondrodysplasia with spastic paraparesis and intracranial calcification: case-based review. Rheumatol Int. 2020;40(11):1903\u201310.","journal-title":"Rheumatol Int"},{"issue":"6","key":"1207_CR17","doi-asserted-by":"publisher","first-page":"e13411","DOI":"10.1111\/sji.13411","volume":"100","author":"M Sestan","year":"2024","unstructured":"Sestan M, et al. Whole exome sequencing in patients with childhood-onset systemic lupus erythematosus: results from a Croatian National study. Scand J Immunol. 2024;100(6):e13411.","journal-title":"Scand J Immunol"},{"issue":"6","key":"1207_CR18","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s10875-023-01506-7","volume":"43","author":"L Zhou","year":"2023","unstructured":"Zhou L, et al. An early-onset SLE patient with a novel paternal inherited BACH2 mutation. J Clin Immunol. 2023;43(6):1367\u201378.","journal-title":"J Clin Immunol"},{"key":"1207_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2024-001436","author":"A Sayadi","year":"2025","unstructured":"Sayadi A, et al. Rare and common single nucleotide variants in childhood-onset systemic lupus erythematosus. Lupus Sci Med. 2025. https:\/\/doi.org\/10.1136\/lupus-2024-001436.","journal-title":"Lupus Sci Med"},{"key":"1207_CR20","doi-asserted-by":"publisher","first-page":"119898","DOI":"10.1016\/j.cca.2024.119898","volume":"563","author":"H Lin","year":"2024","unstructured":"Lin H, et al. A CD3G homozygous pathogenic variant in a Chinese child with lupus-like disease, autoimmune thyroiditis and immunodeficiency. Clin Chim Acta. 2024;563:119898.","journal-title":"Clin Chim Acta"},{"issue":"10","key":"1207_CR21","doi-asserted-by":"publisher","first-page":"5388","DOI":"10.1093\/rheumatology\/keaf304","volume":"64","author":"J Alshekaili","year":"2025","unstructured":"Alshekaili J, et al. Single-centre comparison of non-familial, Familial and Monogenic lupus. Rheumatology (Oxford). 2025;64(10):5388\u201395.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"1207_CR22","doi-asserted-by":"publisher","first-page":"104262","DOI":"10.1016\/j.ejmg.2021.104262","volume":"64","author":"RM Kisla Ekinci","year":"2021","unstructured":"Kisla Ekinci RM, et al. Monogenic lupus due to DNASE1L3 deficiency in a pediatric patient with urticarial rash, hypocomplementemia, pulmonary hemorrhage, and immune-complex glomerulonephritis. Eur J Med Genet. 2021;64(9):104262.","journal-title":"Eur J Med Genet"},{"issue":"6","key":"1207_CR23","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1053\/j.ajkd.2024.05.014","volume":"84","author":"S Volpi","year":"2024","unstructured":"Volpi S, et al. Lupus nephritis patterns and response to type I interferon in patients with DNASE1L3 variants: report of three cases. Am J Kidney Dis. 2024;84(6):791\u20137.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"1207_CR24","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1007\/s10875-022-01287-5","volume":"42","author":"M Tusseau","year":"2022","unstructured":"Tusseau M, et al. DNASE1L3 deficiency, new phenotypes, and evidence for a transient type I IFN signaling. J Clin Immunol. 2022;42(6):1310\u201320.","journal-title":"J Clin Immunol"},{"issue":"7","key":"1207_CR25","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1093\/rheumatology\/keae679","volume":"64","author":"R Abdwani","year":"2025","unstructured":"Abdwani R, et al. A deep dive into Monogenic lupus: insights on DNASE1L3 mutation. Rheumatology (Oxford). 2025;64(7):4331\u20134.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"1207_CR26","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1111\/1756-185X.14826","volume":"26","author":"S Basu","year":"2023","unstructured":"Basu S, et al. A young Boy with rash, arthritis, and developmental delay: Monogenic lupus due to DNASE2 gene defect. Int J Rheum Dis. 2023;26(12):2599\u2013602.","journal-title":"Int J Rheum Dis"},{"key":"1207_CR27","doi-asserted-by":"publisher","first-page":"109731","DOI":"10.1016\/j.clim.2023.109731","volume":"255","author":"Q Wang","year":"2023","unstructured":"Wang Q, et al. NLRC4 gain-of-function variant is identified in a patient with systemic lupus erythematosus. Clin Immunol. 2023;255:109731.","journal-title":"Clin Immunol"},{"key":"1207_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09513-x","author":"Q Wang","year":"2025","unstructured":"Wang Q, et al. Loss-of-function mutations in PLD4 lead to systemic lupus erythematosus. Nature. 2025. https:\/\/doi.org\/10.1038\/s41586-025-09513-x.","journal-title":"Nature"},{"key":"1207_CR29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20232337","author":"M Jeanpierre","year":"2024","unstructured":"Jeanpierre M, et al. Haploinsufficiency in PTPN2 leads to early-onset systemic autoimmunity from Evans syndrome to lupus. J Exp Med. 2024. https:\/\/doi.org\/10.1084\/jem.20232337.","journal-title":"J Exp Med"},{"issue":"12","key":"1207_CR30","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1136\/ard-2022-222795","volume":"81","author":"L Xu","year":"2022","unstructured":"Xu L, et al. Loss-of-function variants in SAT1 cause X-linked childhood-onset systemic lupus erythematosus. Ann Rheum Dis. 2022;81(12):1712\u201321.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1207_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12969-023-00939-z","volume":"22","author":"P Moran-Alvarez","year":"2024","unstructured":"Moran-Alvarez P, et al. Monogenic systemic lupus erythematosus onset in a 13-year-old Boy with Noonan like-syndrome: a case report and literature review. Pediatr Rheumatol Online J. 2024;22(1):17.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"8","key":"1207_CR32","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1093\/rheumatology\/keaf144","volume":"64","author":"B Menentoglu","year":"2025","unstructured":"Menentoglu B, et al. Complex crosstalk: early-onset lupus and antiphospholipid syndrome in a child with SHOC2-related rasopathy. Rheumatology (Oxford). 2025;64(8):4852\u20133.","journal-title":"Rheumatology (Oxford)"},{"key":"1207_CR33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI179193","author":"J Stremenova Spegarova","year":"2024","unstructured":"Stremenova Spegarova J, et al. A de novo TLR7 gain-of-function mutation causing severe monogenic lupus in an infant. J Clin Invest. 2024. https:\/\/doi.org\/10.1172\/JCI179193.","journal-title":"J Clin Invest"},{"issue":"7909","key":"1207_CR34","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41586-022-04642-z","volume":"605","author":"GJ Brown","year":"2022","unstructured":"Brown GJ, et al. Tlr7 gain-of-function genetic variation causes human lupus. Nature. 2022;605(7909):349\u201356.","journal-title":"Nature"},{"issue":"92","key":"1207_CR35","doi-asserted-by":"publisher","first-page":"eadi9769","DOI":"10.1126\/sciimmunol.adi9769","volume":"9","author":"C Wolf","year":"2024","unstructured":"Wolf C, et al. UNC93B1 variants underlie TLR7-dependent autoimmunity. Sci Immunol. 2024;9(92):eadi9769.","journal-title":"Sci Immunol"},{"key":"1207_CR36","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20232066","author":"C David","year":"2024","unstructured":"David C, et al. Gain-of-function human UNC93B1 variants cause systemic lupus erythematosus and chilblain lupus. J Exp Med. 2024. https:\/\/doi.org\/10.1084\/jem.20232066.","journal-title":"J Exp Med"},{"issue":"92","key":"1207_CR37","doi-asserted-by":"publisher","first-page":"eadi9575","DOI":"10.1126\/sciimmunol.adi9575","volume":"9","author":"H Mishra","year":"2024","unstructured":"Mishra H, et al. Disrupted degradative sorting of TLR7 is associated with human lupus. Sci Immunol. 2024;9(92):eadi9575.","journal-title":"Sci Immunol"},{"issue":"6","key":"1207_CR38","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41590-024-01846-5","volume":"25","author":"M Al-Azab","year":"2024","unstructured":"Al-Azab M, et al. Genetic variants in UNC93B1 predispose to childhood-onset systemic lupus erythematosus. Nat Immunol. 2024;25(6):969\u201380.","journal-title":"Nat Immunol"},{"key":"1207_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9030712","author":"E Demirkaya","year":"2020","unstructured":"Demirkaya E, et al. New horizons in the genetic etiology of systemic lupus erythematosus and lupus-like disease: monogenic lupus and beyond. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9030712.","journal-title":"J Clin Med"},{"issue":"4","key":"1207_CR40","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/ajmg.c.32027","volume":"190","author":"MI Kavamura","year":"2022","unstructured":"Kavamura MI, Leoni C, Neri G. Dermatological manifestations, management, and care in rasopathies. Am J Med Genet C Semin Med Genet. 2022;190(4):452\u20138.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"1","key":"1207_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3109\/08916930903374832","volume":"43","author":"G Gorelik","year":"2010","unstructured":"Gorelik G, Richardson B. Key role of ERK pathway signaling in lupus. Autoimmunity. 2010;43(1):17\u201322.","journal-title":"Autoimmunity"},{"key":"1207_CR42","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13148-017-0378-7","volume":"9","author":"Z Wang","year":"2017","unstructured":"Wang Z, et al. Translating epigenetics into clinic: focus on lupus. Clin Epigenetics. 2017;9:78.","journal-title":"Clin Epigenetics"},{"key":"1207_CR43","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.3389\/fimmu.2019.01066","volume":"10","author":"JE Molineros","year":"2019","unstructured":"Molineros JE, et al. Mechanistic characterization of RASGRP1 variants identifies an hnRNP-K-regulated transcriptional enhancer contributing to SLE susceptibility. Front Immunol. 2019;10:1066.","journal-title":"Front Immunol"},{"key":"1207_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2024-001345","author":"C Zhang","year":"2025","unstructured":"Zhang C, et al. Ras-MAPK pathway in patients with lupus nephritis. Lupus Sci Med. 2025. https:\/\/doi.org\/10.1136\/lupus-2024-001345.","journal-title":"Lupus Sci Med"},{"key":"1207_CR45","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.136047","author":"P Azar","year":"2020","unstructured":"Azar P, et al. TLR7 dosage polymorphism shapes interferogenesis and HIV-1 acute viremia in women. JCI Insight. 2020. https:\/\/doi.org\/10.1172\/jci.insight.136047.","journal-title":"JCI Insight"},{"issue":"5780","key":"1207_CR46","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1126\/science.1124978","volume":"312","author":"P Pisitkun","year":"2006","unstructured":"Pisitkun P, et al. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science. 2006;312(5780):1669\u201372.","journal-title":"Science"},{"key":"1207_CR47","doi-asserted-by":"publisher","first-page":"p2553901","DOI":"10.1155\/2022\/2553901","volume":"2022","author":"GV Pacheco","year":"2022","unstructured":"Pacheco GV, et al. Copy number variation and frequency of rs179008 in TLR7 gene associated with systemic lupus erythematosus in two Mexican populations. J Immunol Res. 2022;2022:p2553901.","journal-title":"J Immunol Res"},{"key":"1207_CR48","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1038\/srep03792","volume":"4","author":"CM Wang","year":"2014","unstructured":"Wang CM, et al. Genetic variations in Toll-like receptors (TLRs 3\/7\/8) are associated with systemic lupus erythematosus in a Taiwanese population. Sci Rep. 2014;4:3792.","journal-title":"Sci Rep"},{"issue":"36","key":"1207_CR49","doi-asserted-by":"publisher","first-page":"15838","DOI":"10.1073\/pnas.1001337107","volume":"107","author":"N Shen","year":"2010","unstructured":"Shen N, et al. Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proc Natl Acad Sci U S A. 2010;107(36):15838\u201343.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1207_CR50","doi-asserted-by":"publisher","first-page":"103451","DOI":"10.1016\/j.jaut.2025.103451","volume":"155","author":"Y Renaudineau","year":"2025","unstructured":"Renaudineau Y, et al. Common Toll-like receptor 7 variants define disease risk and phenotypes in juvenile-onset systemic lupus erythematosus. J Autoimmun. 2025;155:103451.","journal-title":"J Autoimmun"},{"key":"1207_CR51","doi-asserted-by":"publisher","first-page":"110194","DOI":"10.1016\/j.clim.2024.110194","volume":"262","author":"Y Renaudineau","year":"2024","unstructured":"Renaudineau Y, et al. Type I interferon associated epistasis May contribute to early disease-onset and high disease activity in juvenile-onset lupus. Clin Immunol. 2024;262:110194.","journal-title":"Clin Immunol"},{"issue":"2","key":"1207_CR52","doi-asserted-by":"publisher","first-page":"e1003336","DOI":"10.1371\/journal.pgen.1003336","volume":"9","author":"Y Deng","year":"2013","unstructured":"Deng Y, et al. MicroRNA-3148 modulates allelic expression of toll-like receptor 7 variant associated with systemic lupus erythematosus. PLoS Genet. 2013;9(2):e1003336.","journal-title":"PLoS Genet"},{"issue":"2","key":"1207_CR53","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s10875-024-01660-6","volume":"44","author":"C David","year":"2024","unstructured":"David C, et al. Interface gain-of-function mutations in TLR7 cause systemic and neuro-inflammatory disease. J Clin Immunol. 2024;44(2):60.","journal-title":"J Clin Immunol"},{"issue":"8","key":"1207_CR54","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/imcb.12807","volume":"102","author":"JI Ellyard","year":"2024","unstructured":"Ellyard JI, Gantier MP. Uncovering new causes of monogenic systemic lupus erythematosus. Immunol Cell Biol. 2024;102(8):651\u20134.","journal-title":"Immunol Cell Biol"},{"key":"1207_CR55","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20232005","author":"VE Rael","year":"2024","unstructured":"Rael VE, et al. Large-scale mutational analysis identifies UNC93B1 variants that drive TLR-mediated autoimmunity in mice and humans. J Exp Med. 2024. https:\/\/doi.org\/10.1084\/jem.20232005.","journal-title":"J Exp Med"},{"key":"1207_CR56","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clim.2016.03.002","volume":"165","author":"CM Hedrich","year":"2016","unstructured":"Hedrich CM. Shaping the spectrum - from autoinflammation to autoimmunity. Clin Immunol. 2016;165:21\u20138.","journal-title":"Clin Immunol"},{"key":"1207_CR57","doi-asserted-by":"publisher","first-page":"1288675","DOI":"10.3389\/fimmu.2023.1288675","volume":"14","author":"M Rossano","year":"2023","unstructured":"Rossano M, et al. Novel heterozygous TREX1 mutation in a juvenile systemic lupus erythematosus patient with severe cutaneous involvement treated successfully with Jak-inhibitors: a case report. Front Immunol. 2023;14:1288675.","journal-title":"Front Immunol"},{"issue":"8","key":"1207_CR58","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/ng1845","volume":"38","author":"YJ Crow","year":"2006","unstructured":"Crow YJ, et al. Mutations in the gene encoding the 3\u2019-5\u2019 DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nat Genet. 2006;38(8):917\u201320.","journal-title":"Nat Genet"},{"issue":"4","key":"1207_CR59","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1086\/513443","volume":"80","author":"G Rice","year":"2007","unstructured":"Rice G, et al. Heterozygous mutations in TREX1 cause Familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am J Hum Genet. 2007;80(4):811\u20135.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"1207_CR60","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/91070","volume":"28","author":"K Yasutomo","year":"2001","unstructured":"Yasutomo K, et al. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet. 2001;28(4):313\u20134.","journal-title":"Nat Genet"},{"issue":"1","key":"1207_CR61","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1038\/s41467-017-01932-3","volume":"8","author":"MP Rodero","year":"2017","unstructured":"Rodero MP, et al. Type I interferon-mediated autoinflammation due to DNase II deficiency. Nat Commun. 2017;8(1):2176.","journal-title":"Nat Commun"},{"issue":"1","key":"1207_CR62","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.cell.2016.05.034","volume":"166","author":"V Sisirak","year":"2016","unstructured":"Sisirak V, et al. Digestion of chromatin in apoptotic cell microparticles prevents autoimmunity. Cell. 2016;166(1):88\u2013101.","journal-title":"Cell"},{"issue":"3","key":"1207_CR63","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.rdc.2021.04.001","volume":"47","author":"S Sirobhushanam","year":"2021","unstructured":"Sirobhushanam S, Lazar S, Kahlenberg JM. Interferons in systemic lupus erythematosus. Rheum Dis Clin North Am. 2021;47(3):297\u2013315.","journal-title":"Rheum Dis Clin North Am"},{"key":"1207_CR64","doi-asserted-by":"crossref","unstructured":"Rivada AR et al. The type 1 diabetes candidate genes PTPN2 and BACH2 regulate novel IFN-alpha-induced crosstalk between the JAK\/STAT and MAPKs pathways in human beta cells. Res Sq, 2025.","DOI":"10.21203\/rs.3.rs-6079043\/v1"},{"issue":"8","key":"1207_CR65","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/nrrheum.2013.78","volume":"9","author":"JC Crispin","year":"2013","unstructured":"Crispin JC, Hedrich CM, Tsokos GC. Gene-function studies in systemic lupus erythematosus. Nat Rev Rheumatol. 2013;9(8):476\u201384.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"1207_CR66","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1136\/annrheumdis-2020-219209","volume":"80","author":"X Yin","year":"2021","unstructured":"Yin X, et al. Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus. Ann Rheum Dis. 2021;80(5):632\u201340.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1207_CR67","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1093\/rheumatology\/keab016","volume":"60","author":"Q Song","year":"2021","unstructured":"Song Q, et al. Genome-wide association study on Northern Chinese identifies KLF2, DOT1L and STAB2 associated with systemic lupus erythematosus. Rheumatology (Oxford). 2021;60(9):4407\u201317.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1207_CR68","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s00438-021-01798-7","volume":"296","author":"YM Zhang","year":"2021","unstructured":"Zhang YM, et al. Shared genetic study gives insights into the shared and distinct pathogenic immunity components of IgA nephropathy and SLE. Mol Genet Genomics. 2021;296(4):1017\u201326.","journal-title":"Mol Genet Genomics"},{"issue":"5","key":"1207_CR69","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/art.42021","volume":"74","author":"YF Wang","year":"2022","unstructured":"Wang YF, et al. Identification of shared and Asian-Specific loci for systemic lupus erythematosus and evidence for roles of type III interferon signaling and lysosomal function in the disease: A Multi-Ancestral Genome-Wide association study. Arthritis Rheumatol. 2022;74(5):840\u20138.","journal-title":"Arthritis Rheumatol"},{"key":"1207_CR70","doi-asserted-by":"publisher","first-page":"16021","DOI":"10.1038\/ncomms16021","volume":"8","author":"CD Langefeld","year":"2017","unstructured":"Langefeld CD, et al. Transancestral mapping and genetic load in systemic lupus erythematosus. Nat Commun. 2017;8:16021.","journal-title":"Nat Commun"},{"issue":"8","key":"1207_CR71","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/ng.3603","volume":"48","author":"DL Morris","year":"2016","unstructured":"Morris DL, et al. Genome-wide association meta-analysis in Chinese and European individuals identifies ten new loci associated with systemic lupus erythematosus. Nat Genet. 2016;48(8):940\u20136.","journal-title":"Nat Genet"},{"issue":"1","key":"1207_CR72","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41467-021-21049-y","volume":"12","author":"YF Wang","year":"2021","unstructured":"Wang YF, et al. Identification of 38 novel loci for systemic lupus erythematosus and genetic heterogeneity between ancestral groups. Nat Commun. 2021;12(1):772.","journal-title":"Nat Commun"},{"issue":"10","key":"1207_CR73","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41588-021-00931-x","volume":"53","author":"S Sakaue","year":"2021","unstructured":"Sakaue S, et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet. 2021;53(10):1415\u201324.","journal-title":"Nat Genet"},{"key":"1207_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/flupu.2024.1398035","author":"V Laurynenka","year":"2024","unstructured":"Laurynenka V, Harley JB. The 330 risk loci known for systemic lupus erythematosus (SLE): a review. Front Lupus. 2024. https:\/\/doi.org\/10.3389\/flupu.2024.1398035.","journal-title":"Front Lupus"},{"key":"1207_CR75","doi-asserted-by":"crossref","unstructured":"Alarc\u00f3n-Riquelme MER. R.D., Rare variants in systemic lupus erythematosus: from Monogenic to polygenic disease. Med Res Arch [Internet], 2023. 11(10).","DOI":"10.18103\/mra.v11i10.4363"},{"key":"1207_CR76","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2024-001475","author":"L Lewandowski","year":"2025","unstructured":"Lewandowski L, et al. Next generation sequencing analysis reveals complex genetic architecture of childhood-onset systemic lupus erythematosus. Lupus Sci Med. 2025. https:\/\/doi.org\/10.1136\/lupus-2024-001475.","journal-title":"Lupus Sci Med"},{"issue":"1","key":"1207_CR77","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1136\/ard.2010.141697","volume":"70","author":"R Webb","year":"2011","unstructured":"Webb R, et al. Early disease onset is predicted by a higher genetic risk for lupus and is associated with a more severe phenotype in lupus patients. Ann Rheum Dis. 2011;70(1):151\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1207_CR78","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S1672-0229(03)01036-2","volume":"1","author":"C Yan","year":"2003","unstructured":"Yan C, et al. HLA-A gene polymorphism defined by high-resolution sequence-based typing in 161 Northern Chinese Han people. Genomics Proteom Bioinf. 2003;1(4):304\u20139.","journal-title":"Genomics Proteom Bioinf"},{"issue":"4","key":"1207_CR79","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1056\/NEJM197107222850403","volume":"285","author":"FC Grumet","year":"1971","unstructured":"Grumet FC, et al. Histocompatibility (HL-A) antigens associated with systemic lupus erythematosus. A possible genetic predisposition to disease. N Engl J Med. 1971;285(4):193\u20136.","journal-title":"N Engl J Med"},{"issue":"2","key":"1207_CR80","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1399-0039.1971.tb00080.x","volume":"1","author":"H Waters","year":"1971","unstructured":"Waters H, Konrad P, Walford RL. The distribution of HL-A histocompatibility factors and genes in patients with systemic lupus erythematosus. Tissue Antigens. 1971;1(2):68\u201373.","journal-title":"Tissue Antigens"},{"issue":"1","key":"1207_CR81","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s42003-023-05496-5","volume":"6","author":"G Butler-Laporte","year":"2023","unstructured":"Butler-Laporte G, et al. HLA allele-calling using multi-ancestry whole-exome sequencing from the UK biobank identifies 129 novel associations in 11 autoimmune diseases. Commun Biol. 2023;6(1):1113.","journal-title":"Commun Biol"},{"key":"1207_CR82","doi-asserted-by":"publisher","first-page":"100268","DOI":"10.1016\/j.jtauto.2025.100268","volume":"10","author":"Y Renaudineau","year":"2025","unstructured":"Renaudineau Y, et al. Across ancestries, HLA-B *08:01 approximately DRB1 *03:01 (DR3) and HLA-DQA *01:02 (DR2) increase the risk to develop juvenile-onset systemic lupus erythematosus through low complement C4 levels. J Transl Autoimmun. 2025;10:100268.","journal-title":"J Transl Autoimmun"},{"issue":"1","key":"1207_CR83","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/rheumatology\/kez220","volume":"59","author":"D Webber","year":"2020","unstructured":"Webber D, et al. Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE. Rheumatology (Oxford). 2020;59(1):90\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"1207_CR84","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003293","author":"YJ Chen","year":"2024","unstructured":"Chen YJ, et al. Polygenic risk score predicts earlier-onset adult systemic lupus erythematosus and first-year renal diseases in a Taiwanese cohort. RMD Open. 2024. https:\/\/doi.org\/10.1136\/rmdopen-2023-003293.","journal-title":"RMD Open"},{"issue":"9","key":"1207_CR85","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1093\/rheumatology\/kead016","volume":"62","author":"D Webber","year":"2023","unstructured":"Webber D, et al. Genetics of osteonecrosis in children and adults with systemic lupus erythematosus. Rheumatology (Oxford). 2023;62(9):3205\u201312.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1207_CR86","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/s41467-023-36306-5","volume":"14","author":"C Khunsriraksakul","year":"2023","unstructured":"Khunsriraksakul C, et al. Multi-ancestry and multi-trait genome-wide association meta-analyses inform clinical risk prediction for systemic lupus erythematosus. Nat Commun. 2023;14(1):668.","journal-title":"Nat Commun"},{"key":"1207_CR87","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbae240","author":"J Schwarzerova","year":"2024","unstructured":"Schwarzerova J, et al. A perspective on genetic and polygenic risk scores-advances and limitations and overview of associated tools. Brief Bioinform. 2024. https:\/\/doi.org\/10.1093\/bib\/bbae240.","journal-title":"Brief Bioinform"},{"key":"1207_CR88","doi-asserted-by":"publisher","first-page":"110540","DOI":"10.1016\/j.clim.2025.110540","volume":"279","author":"V Natoli","year":"2025","unstructured":"Natoli V, et al. Genetic variability associates with ancestry, age at disease onset, organ involvement and disease severity in juvenile-onset systemic lupus erythematosus. Clin Immunol. 2025;279:110540.","journal-title":"Clin Immunol"},{"issue":"6","key":"1207_CR89","doi-asserted-by":"publisher","first-page":"852","DOI":"10.3899\/jrheum.200002","volume":"48","author":"D Dominguez","year":"2021","unstructured":"Dominguez D, et al. Relationship between genetic risk and age of diagnosis in systemic lupus erythematosus. J Rheumatol. 2021;48(6):852\u20138.","journal-title":"J Rheumatol"},{"issue":"11","key":"1207_CR90","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1093\/rheumatology\/kead119","volume":"62","author":"TS Tang","year":"2023","unstructured":"Tang TS, et al. Genetics of longitudinal kidney function in children and adults with systemic lupus erythematosus. Rheumatology (Oxford). 2023;62(11):3749\u201356.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1207_CR91","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s41588-019-0379-x","volume":"51","author":"AR Martin","year":"2019","unstructured":"Martin AR, et al. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet. 2019;51(4):584\u201391.","journal-title":"Nat Genet"},{"issue":"1","key":"1207_CR92","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1038\/s41467-019-11112-0","volume":"10","author":"L Duncan","year":"2019","unstructured":"Duncan L, et al. Analysis of polygenic risk score usage and performance in diverse human populations. Nat Commun. 2019;10(1):3328.","journal-title":"Nat Commun"},{"issue":"7","key":"1207_CR93","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nrg.2016.27","volume":"17","author":"N Chatterjee","year":"2016","unstructured":"Chatterjee N, Shi J, Garcia-Closas M. Developing and evaluating polygenic risk prediction models for stratified disease prevention. Nat Rev Genet. 2016;17(7):392\u2013406.","journal-title":"Nat Rev Genet"},{"issue":"7","key":"1207_CR94","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/ng.3285","volume":"47","author":"TJ Polderman","year":"2015","unstructured":"Polderman TJ, et al. Meta-analysis of the heritability of human traits based on Fifty years of twin studies. Nat Genet. 2015;47(7):702\u20139.","journal-title":"Nat Genet"},{"issue":"7265","key":"1207_CR95","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nature08494","volume":"461","author":"TA Manolio","year":"2009","unstructured":"Manolio TA, et al. Finding the missing heritability of complex diseases. Nature. 2009;461(7265):747\u201353.","journal-title":"Nature"},{"issue":"12","key":"1207_CR96","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie R, et al. Two-year, randomized, controlled trial of Belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117\u201328.","journal-title":"N Engl J Med"},{"issue":"2","key":"1207_CR97","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/art.39962","volume":"69","author":"R Furie","year":"2017","unstructured":"Furie R, et al. Anifrolumab, an Anti-Interferon-alpha receptor monoclonal Antibody, in Moderate-to-Severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69(2):376\u201386.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"1207_CR98","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med. 2021;385(6):567\u20139.","journal-title":"N Engl J Med"},{"key":"1207_CR99","doi-asserted-by":"crossref","unstructured":"Li CZ, Yu J, Li H, Yang Z, Lu S, Feng M, Li Q, Sun X, Tang L, Chen X, Wang J, Assudani C. D., A phase 4, multicentre, open-label study of intravenous belimumab in paediatric patients with active systemic lupus erythematosus in China. Annals of the Rheumatic Diseases, 2025. Volume 84.","DOI":"10.1016\/j.ard.2025.06.1928"},{"key":"1207_CR100","unstructured":"Brunner HOV, Dimelow D, Calvo Penad\u00e9s R, Wilkinson I, Cruz Rizo Rodriguez C, Boteanu J, Kamphuis A, Minden S, Horneff K, Anton G, Mori J, Yamasaki M, Olaiz Y, Marino J, van Maurik R, Okily A, Yanni M, Wilde E. P., Pharmacokinetic, Pharmacodynamic, and Safety Profile of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: Analysis of Data from a Multicenter, Open-Label Trial. Arthritis Rheumatol., 2023. 75."},{"issue":"11","key":"1207_CR101","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","volume":"74","author":"D Isenberg","year":"2015","unstructured":"Isenberg D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015;74(11):2006\u201315.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1207_CR102","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1093\/rheumatology\/keab877","volume":"61","author":"S Goklemez","year":"2022","unstructured":"Goklemez S, et al. Long-term follow-up after lymphodepleting autologous Haematopoietic cell transplantation for treatment-resistant systemic lupus erythematosus. Rheumatology (Oxford). 2022;61(8):3317\u201328.","journal-title":"Rheumatology (Oxford)"},{"key":"1207_CR103","unstructured":"Clowse MI, Merrill D, D\u00f6rner J, Petri T, Vital M, Morand E, Jimenez E, Brookes T, Gaiha-Rohrbach S, Martin J, Nelde C, Stach A. C., Demonstrated significant improvement in systemic lupus erythematosus disease activity: efficacy and safety results of a phase 3 trial. Arthritis Rheumatol, 2024. 76."},{"issue":"2","key":"1207_CR104","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1053\/j.ajkd.2010.08.036","volume":"57","author":"W Chen","year":"2011","unstructured":"Chen W, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis. 2011;57(2):235\u201344.","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"1207_CR105","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.38790","volume":"66","author":"AT Group","year":"2014","unstructured":"Group AT. Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheumatol. 2014;66(11):3096\u2013104.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1207_CR106","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s13287-018-1053-4","volume":"9","author":"J Liang","year":"2018","unstructured":"Liang J, et al. Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study. Stem Cell Res Ther. 2018;9(1):312.","journal-title":"Stem Cell Res Ther"},{"issue":"8","key":"1207_CR107","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1136\/annrheumdis-2017-211073","volume":"76","author":"D Deng","year":"2017","unstructured":"Deng D, et al. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann Rheum Dis. 2017;76(8):1436\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1207_CR108","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.2215\/CJN.02520322","volume":"17","author":"R Furie","year":"2022","unstructured":"Furie R, et al. Safety and efficacy of Belimumab in patients with lupus nephritis: Open-Label extension of BLISS-LN study. Clin J Am Soc Nephrol. 2022;17(11):1620\u201330.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1207_CR109","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001747","author":"HI Brunner","year":"2021","unstructured":"Brunner HI, et al. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD Open. 2021. https:\/\/doi.org\/10.1136\/rmdopen-2021-001747.","journal-title":"RMD Open"},{"issue":"14","key":"1207_CR110","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1177\/09612033241299175","volume":"33","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, et al. Belimumab safety in adult and paediatric Chinese patients with systemic lupus erythematosus: A phase 4, multicentre, observational study. Lupus. 2024;33(14):1562\u201372.","journal-title":"Lupus"},{"issue":"9","key":"1207_CR111","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1177\/09612033231187752","volume":"32","author":"JE Roberts","year":"2023","unstructured":"Roberts JE, et al. Real-world use and outcomes of Belimumab in childhood-onset lupus: A single-center retrospective study. Lupus. 2023;32(9):1111\u20136.","journal-title":"Lupus"},{"issue":"1","key":"1207_CR112","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222\u201333.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1207_CR113","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin BH, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64(4):1215\u201326.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1207_CR114","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15\u201329.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1207_CR115","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.1093\/rheumatology\/keaf231","volume":"64","author":"J Cognard","year":"2025","unstructured":"Cognard J, et al. Indications, efficacy and safety of rituximab in childhood-onset systemic lupus erythematosus: a retrospective study of the JIR cohort. Rheumatology (Oxford). 2025;64(9):4921\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1207_CR116","doi-asserted-by":"publisher","first-page":"98393","DOI":"10.5527\/wjn.v13.i4.98393","volume":"13","author":"E Kalashnikova","year":"2024","unstructured":"Kalashnikova E, et al. Outcomes of a 12-month course of early and late rituximab BCD020 biosimilar administration in juvenile systemic lupus erythematosus: A retrospective study. World J Nephrol. 2024;13(4):98393.","journal-title":"World J Nephrol"},{"issue":"12","key":"1207_CR117","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1007\/s00467-023-06025-6","volume":"38","author":"EY Chan","year":"2023","unstructured":"Chan EY, et al. Long-term outcomes with rituximab as add-on therapy in severe childhood-onset lupus nephritis. Pediatr Nephrol. 2023;38(12):4001\u201311.","journal-title":"Pediatr Nephrol"},{"key":"1207_CR118","doi-asserted-by":"publisher","first-page":"1525892","DOI":"10.3389\/fimmu.2025.1525892","volume":"16","author":"DS Chiarenza","year":"2025","unstructured":"Chiarenza DS, et al. Case report: single infusion of combined anti-CD20 and anti-CD38 monoclonal antibodies in pediatric refractory lupus nephritis. Front Immunol. 2025;16:1525892.","journal-title":"Front Immunol"},{"issue":"15","key":"1207_CR119","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","volume":"392","author":"RA Furie","year":"2025","unstructured":"Furie RA, et al. Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med. 2025;392(15):1471\u201383.","journal-title":"N Engl J Med"},{"key":"1207_CR120","unstructured":"Fanouriakis A, et al. EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update. Ann Rheum Dis; 2025."},{"issue":"12","key":"1207_CR121","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2215\/CJN.0000000000000288","volume":"18","author":"C Dossier","year":"2023","unstructured":"Dossier C, et al. Obinutuzumab in frequently relapsing and Steroid-Dependent nephrotic syndrome in children. Clin J Am Soc Nephrol. 2023;18(12):1555\u201362.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"1207_CR122","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1016\/j.ekir.2025.06.019","volume":"10","author":"A Angeletti","year":"2025","unstructured":"Angeletti A, et al. Obinutuzumab in Rituximab-Resistant podocytopathies: A Single-Center experience. Kidney Int Rep. 2025;10(8):2873\u20134.","journal-title":"Kidney Int Rep"},{"issue":"7","key":"1207_CR123","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s10067-023-06559-y","volume":"42","author":"RF Modica","year":"2023","unstructured":"Modica RF, et al. Bortezomib is efficacious in the treatment of severe childhood-onset neuropsychiatric systemic lupus erythematosus with psychosis: a case series and mini-review of B-cell immunomodulation in antibody-mediated diseases. Clin Rheumatol. 2023;42(7):1965\u201379.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"1207_CR124","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F Muller","year":"2024","unstructured":"Muller F, et al. CD19 CAR T-Cell therapy in autoimmune Disease - A case series with Follow-up. N Engl J Med. 2024;390(8):687\u2013700.","journal-title":"N Engl J Med"},{"issue":"8","key":"1207_CR125","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41584-025-01272-3","volume":"21","author":"H Wobma","year":"2025","unstructured":"Wobma H, et al. CAR T cell therapy for children with rheumatic disease: the time is now. Nat Rev Rheumatol. 2025;21(8):494\u2013506.","journal-title":"Nat Rev Rheumatol"},{"issue":"10437","key":"1207_CR126","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","volume":"403","author":"T Krickau","year":"2024","unstructured":"Krickau T, et al. CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis. Lancet. 2024;403(10437):1627\u201330.","journal-title":"Lancet"},{"issue":"1","key":"1207_CR127","doi-asserted-by":"publisher","first-page":"103692","DOI":"10.1016\/j.autrev.2024.103692","volume":"24","author":"X He","year":"2025","unstructured":"He X, et al. Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells. Autoimmun Rev. 2025;24(1):103692.","journal-title":"Autoimmun Rev"},{"key":"1207_CR128","doi-asserted-by":"crossref","unstructured":"Marasco EB, Merli C, Alvarez P, Nicolai PM, Algeri R. M; P101 Anti-CD19 CAR-T cell therapy for refractory childhood-onset systemic lupus erythematosus. BMJ, 2024. https:\/\/lupus.bmj.com\/content\/11\/Suppl_1\/A113.1","DOI":"10.1136\/lupus-2024-el.155"},{"issue":"6","key":"1207_CR129","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.1016\/S2665-9913(25)00091-8","volume":"7","author":"M Hagen","year":"2025","unstructured":"Hagen M, et al. Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study. Lancet Rheumatol. 2025;7(6):e424\u201333.","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"1207_CR130","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1056\/NEJMc2408786","volume":"391","author":"M Hagen","year":"2024","unstructured":"Hagen M, et al. BCMA-targeted T-cell-engager therapy for autoimmune disease. N Engl J Med. 2024;391(9):867\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"1207_CR131","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13075-025-03564-1","volume":"27","author":"M Jouret","year":"2025","unstructured":"Jouret M, et al. CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future? Arthritis Res Ther. 2025;27(1):102.","journal-title":"Arthritis Res Ther"},{"key":"1207_CR132","unstructured":"Tur C, et al. Effects of different B-cell-depleting strategies on the lymphatic tissue. Ann Rheum Dis; 2025."},{"issue":"6","key":"1207_CR133","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","volume":"30","author":"L Bucci","year":"2024","unstructured":"Bucci L, et al. Bispecific T cell engager therapy for refractory rheumatoid arthritis. Nat Med. 2024;30(6):1593\u2013601.","journal-title":"Nat Med"},{"key":"1207_CR134","doi-asserted-by":"publisher","first-page":"114071","DOI":"10.1016\/j.ejca.2024.114071","volume":"204","author":"M Subklewe","year":"2024","unstructured":"Subklewe M, et al. Application of blinatumomab, a bispecific anti-CD3\/CD19 T-cell engager, in treating severe systemic sclerosis: A case study. Eur J Cancer. 2024;204:114071.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1207_CR135","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu D, et al. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2024;83(4):475\u201387.","journal-title":"Ann Rheum Dis"},{"key":"1207_CR136","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1136\/annrheumdis-2023-eular.3110","volume":"1","author":"JI Cort\u00e9s-Hern\u00e1ndez","year":"2023","unstructured":"Cort\u00e9s-Hern\u00e1ndez JI, Gordienko S, Agmon-Levin A, Narongroeknawin N, Romanowska-Prochnicka P. POS0120 SAFETY AND EFFICACY OF SUBCUTANEOUS (S.C.) DOSE IANALUMAB (VAY736; ANTI-BAFFR mAb) ADMINISTERED MONTHLY OVER 28 WEEKS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). Ann Rheum Dis. 2023;1:82:275\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1207_CR137","doi-asserted-by":"crossref","unstructured":"Agmon-Levin NI, Gordienko S, Cort\u00e9s-Hern\u00e1ndez A, Narongroeknawin J, Romanowska-Prochnicka P, Shen K, Cifersk\u00e1 N, Kodera H, Wei M, Leszczynski JCC, Lan P, Mysler JL, Wojciechowski E, Tarr R, Vishneva T, Chen E, Kaneko YH, Finzel Y, Hoi S, Okada A, Koolvisoot M, Lee A, Dai SS, Kaneko L, Rojkovich H, Sun B, Zotkin L, Viallard E, Katayama JF, Magallares M, Sengupta BP, Sips T, Lau C, Avrameas C, Oliver A. S., Phase 2 safety and efficacy of subcutaneous (S.C.) dose ianalumab (VAY736; ANTI-BAFFR mAb) administered every 4 weeks up to 48 weeks in patients with systemic lupus erythematosus (SLE). Ann Rheum Dis, 2024. 83.","DOI":"10.1136\/annrheumdis-2024-eular.634"},{"issue":"11","key":"1207_CR138","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","volume":"60","author":"RA Furie","year":"2021","unstructured":"Furie RA, et al. Phase 2, randomized, placebo-controlled trial of dapirolizumab Pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology (Oxford). 2021;60(11):5397\u2013407.","journal-title":"Rheumatology (Oxford)"},{"key":"1207_CR139","first-page":"10","volume":"52","author":"AC Askanase","year":"2025","unstructured":"Askanase AC, Gladman A, Werth DD, Yusof VP, Gaiha-Rohrbach Y, Jimenez J, Koch T, Koncz ED, Nelde \u00c1, Van Vollenhoven A. MPROVEMENTS OBSERVED IN SKIN AND JOINT MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS WITH DAPIROLIZUMAB PEGOL TREATMENT: RESULTS FROM A PHASE 3 TRIAL. J Rhuematol. 2025;52:10\u20131.","journal-title":"J Rhuematol"},{"key":"1207_CR140","first-page":"11","volume":"52","author":"ZA Touma","year":"2025","unstructured":"Touma ZA, Parodis C, Ramsey-Goldman I, Schneider R, De La Loge M, Jimenez C, Nejati T, Arnaud M. DAPIROLIZUMAB PEGOL DEMONSTRATED IMPROVEMENT IN QUALITY OF LIFE OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: LUPUSQOL RESULTS FROM A PHASE 3 TRIAL. J Rhuematol. 2025;52:11\u20132.","journal-title":"J Rhuematol"},{"issue":"4","key":"1207_CR141","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","volume":"1","author":"RA Furie","year":"2019","unstructured":"Furie RA, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1(4):e208\u201319.","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"1207_CR142","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"1207_CR143","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/art.42392","volume":"75","author":"KC Kalunian","year":"2023","unstructured":"Kalunian KC, et al. A Randomized, Placebo-Controlled phase III extension trial of the Long-Term safety and tolerability of anifrolumab in active systemic lupus erythematosus. Arthritis Rheumatol. 2023;75(2):253\u201365.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"1207_CR144","doi-asserted-by":"publisher","first-page":"e2338200","DOI":"10.1001\/jamanetworkopen.2023.38200","volume":"6","author":"KS Shaw","year":"2023","unstructured":"Shaw KS, et al. Anifrolumab for adolescent discoid lupus erythematosus. JAMA Netw Open. 2023;6(10):e2338200.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"1207_CR145","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/09612033251330094","volume":"34","author":"M Shmizu","year":"2025","unstructured":"Shmizu M, et al. Anifrolumab for refractory cutaneous lupus lesions in pediatric systemic lupus erythematosus. Lupus. 2025;34(5):533\u20136.","journal-title":"Lupus"},{"key":"1207_CR146","unstructured":"Khosroshahi AW, Wang S, Larson L, Jain D. N., Fficacy and safety results from a phase 2 trial of daxdilimab in patients with systemic lupus erythematosus. Arthritis Rheumatol, 2024. 76."},{"issue":"10381","key":"1207_CR147","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","volume":"401","author":"EF Morand","year":"2023","unstructured":"Morand EF, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet. 2023;401(10381):1001\u201310.","journal-title":"Lancet"},{"issue":"10381","key":"1207_CR148","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","volume":"401","author":"M Petri","year":"2023","unstructured":"Petri M, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet. 2023;401(10381):1011\u20139.","journal-title":"Lancet"},{"issue":"2","key":"1207_CR149","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.42391","volume":"75","author":"E Morand","year":"2023","unstructured":"Morand E, et al. Deucravacitinib, a tyrosine kinase 2 Inhibitor, in systemic lupus erythematosus: A phase II, Randomized, Double-Blind, Placebo-Controlled trial. Arthritis Rheumatol. 2023;75(2):242\u201352.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"1207_CR150","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/art.42926","volume":"76","author":"JT Merrill","year":"2024","unstructured":"Merrill JT, et al. Efficacy and safety of Upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: A phase 2 randomized controlled trial. Arthritis Rheumatol. 2024;76(10):1518\u201329.","journal-title":"Arthritis Rheumatol"},{"key":"1207_CR151","doi-asserted-by":"publisher","first-page":"1457821","DOI":"10.3389\/fimmu.2024.1457821","volume":"15","author":"L Hou","year":"2024","unstructured":"Hou L, et al. Tofacitinib for child-onset systemic lupus erythematosus. Front Immunol. 2024;15:1457821.","journal-title":"Front Immunol"},{"key":"1207_CR152","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207767","author":"A Pin","year":"2020","unstructured":"Pin A, et al. Biological and clinical changes in a pediatric series treated with off-label JAK inhibitors. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21207767.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1207_CR153","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1177\/0961203313502864","volume":"22","author":"CC Mok","year":"2013","unstructured":"Mok CC, et al. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study. Lupus. 2013;22(11):1135\u201341.","journal-title":"Lupus"},{"issue":"3","key":"1207_CR154","doi-asserted-by":"publisher","first-page":"e224492","DOI":"10.1001\/jamanetworkopen.2022.4492","volume":"5","author":"Z Zheng","year":"2022","unstructured":"Zheng Z, et al. Effect of tacrolimus vs intravenous cyclophosphamide on complete or partial response in patients with lupus nephritis: A randomized clinical trial. JAMA Netw Open. 2022;5(3):e224492.","journal-title":"JAMA Netw Open"},{"issue":"10289","key":"1207_CR155","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397(10289):2070\u201380.","journal-title":"Lancet"},{"issue":"1","key":"1207_CR156","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/art.42657","volume":"76","author":"A Saxena","year":"2024","unstructured":"Saxena A, et al. Safety and efficacy of Long-Term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial. Arthritis Rheumatol. 2024;76(1):59\u201367.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"1207_CR157","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1002\/art.43212","volume":"77","author":"LR Sammaritano","year":"2025","unstructured":"Sammaritano LR, et al. 2024 American college of rheumatology (ACR) guideline for the Screening, Treatment, and management of lupus nephritis. Arthritis Rheumatol. 2025;77(9):1115\u201335.","journal-title":"Arthritis Rheumatol"},{"issue":"1S","key":"1207_CR158","first-page":"pS1","volume":"105","author":"G Kidney Disease: Improving Global Ou","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes Lupus Nephritis Work G. KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024;105(1S):pS1\u2013S69.","journal-title":"Kidney Int"},{"issue":"5","key":"1207_CR159","first-page":"e38848","volume":"15","author":"R Baum","year":"2023","unstructured":"Baum R, et al. Treatment using both voclosporin and Belimumab in four patients with lupus nephritis. Cureus. 2023;15(5):e38848.","journal-title":"Cureus"},{"key":"1207_CR160","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-025-02361-y","author":"N Ebrahimi","year":"2025","unstructured":"Ebrahimi N, et al. Effective management of lupus nephritis using a novel combination therapy with low-dose steroids: a case report. J Nephrol. 2025. https:\/\/doi.org\/10.1007\/s40620-025-02361-y.","journal-title":"J Nephrol"},{"issue":"12","key":"1207_CR161","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1007\/s10067-022-06325-6","volume":"41","author":"T Nakai","year":"2022","unstructured":"Nakai T, et al. Effect and safety profile of Belimumab and tacrolimus combination therapy in thirty-three patients with systemic lupus erythematosus. Clin Rheumatol. 2022;41(12):3735\u201345.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"1207_CR162","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/rheumatology\/kead447","volume":"63","author":"EY Chan","year":"2024","unstructured":"Chan EY, et al. Renal relapse in children and adolescents with childhood-onset lupus nephritis: a 20-year study. Rheumatology (Oxford). 2024;63(4):953\u201361.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"1207_CR163","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1093\/ndt\/gfab152","volume":"37","author":"S Demir","year":"2022","unstructured":"Demir S, et al. Long-term renal survival of paediatric patients with lupus nephritis. Nephrol Dial Transpl. 2022;37(6):1069\u201377.","journal-title":"Nephrol Dial Transpl"},{"issue":"5","key":"1207_CR164","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1177\/0961203319836712","volume":"28","author":"E Smith","year":"2019","unstructured":"Smith E, et al. Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis. Lupus. 2019;28(5):613\u201320.","journal-title":"Lupus"},{"key":"1207_CR165","doi-asserted-by":"publisher","first-page":"109028","DOI":"10.1016\/j.clim.2022.109028","volume":"239","author":"EMD Smith","year":"2022","unstructured":"Smith EMD, et al. Real world treatment of juvenile-onset systemic lupus erythematosus: data from the UK JSLE cohort study. Clin Immunol. 2022;239:109028.","journal-title":"Clin Immunol"},{"issue":"9","key":"1207_CR166","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1007\/s00431-024-05662-9","volume":"183","author":"H Li","year":"2024","unstructured":"Li H, et al. Efficacy and safety of Belimumab combined with the standard regimen in treating children with lupus nephritis. Eur J Pediatr. 2024;183(9):3987\u201395.","journal-title":"Eur J Pediatr"},{"key":"1207_CR167","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2024-001350","author":"Y Gong","year":"2024","unstructured":"Gong Y, et al. Efficacy of initial combination with belimumab in newly diagnosed childhood-onset lupus nephritis: a single-centre historical control study. Lupus Sci Med. 2024. https:\/\/doi.org\/10.1136\/lupus-2024-001350.","journal-title":"Lupus Sci Med"},{"key":"1207_CR168","doi-asserted-by":"publisher","first-page":"105006","DOI":"10.1016\/j.ejmg.2025.105006","volume":"75","author":"L Hou","year":"2025","unstructured":"Hou L, et al. Short-term efficacy of tofacitinib, a JAK inhibitor, in IFIH1-related Aicardi-Goutieres syndrome. Eur J Med Genet. 2025;75:105006.","journal-title":"Eur J Med Genet"},{"issue":"10","key":"1207_CR169","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1056\/NEJMc2001362","volume":"383","author":"A Vanderver","year":"2020","unstructured":"Vanderver A, et al. Janus kinase Inhibition in the Aicardi-Goutieres syndrome. N Engl J Med. 2020;383(10):986\u20139.","journal-title":"N Engl J Med"},{"issue":"5","key":"1207_CR170","doi-asserted-by":"publisher","first-page":"e63510","DOI":"10.1002\/ajmg.a.63510","volume":"194","author":"C Ryckmans","year":"2024","unstructured":"Ryckmans C, et al. TREX-1 related Aicardi-Goutieres syndrome improved by Janus kinase inhibitor. Am J Med Genet A. 2024;194(5):e63510.","journal-title":"Am J Med Genet A"},{"issue":"5","key":"1207_CR171","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1136\/annrheumdis-2021-221814","volume":"81","author":"K Cetin Gedik","year":"2022","unstructured":"Cetin Gedik K, et al. The 2021 European alliance of associations for rheumatology\/American college of rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE\/PRAAS, SAVI and AGS. Ann Rheum Dis. 2022;81(5):601\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1207_CR172","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1007\/s10875-023-01500-z","volume":"43","author":"ML Fremond","year":"2023","unstructured":"Fremond ML, et al. JAK Inhibition in Aicardi-Goutieres syndrome: a monocentric multidisciplinary Real-World approach study. J Clin Immunol. 2023;43(6):1436\u201347.","journal-title":"J Clin Immunol"},{"issue":"7","key":"1207_CR173","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11926-020-00909-4","volume":"22","author":"I Melki","year":"2020","unstructured":"Melki I, Fremond ML. Type I interferonopathies: from a novel concept to targeted therapeutics. Curr Rheumatol Rep. 2020;22(7):32.","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"1207_CR174","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cei.12115","volume":"175","author":"YJ Crow","year":"2014","unstructured":"Crow YJ, et al. Therapies in Aicardi-Goutieres syndrome. Clin Exp Immunol. 2014;175(1):1\u20138.","journal-title":"Clin Exp Immunol"},{"issue":"22","key":"1207_CR175","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1056\/NEJMc2031081","volume":"383","author":"B Neven","year":"2020","unstructured":"Neven B, et al. JAK Inhibition in the Aicardi-Goutieres syndrome. N Engl J Med. 2020;383(22):2190\u20131.","journal-title":"N Engl J Med"},{"issue":"5","key":"1207_CR176","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s10875-019-00645-0","volume":"39","author":"S Volpi","year":"2019","unstructured":"Volpi S, et al. Efficacy and adverse events during Janus kinase inhibitor treatment of SAVI syndrome. J Clin Immunol. 2019;39(5):476\u201385.","journal-title":"J Clin Immunol"},{"key":"1207_CR177","doi-asserted-by":"publisher","first-page":"825367","DOI":"10.3389\/fimmu.2022.825367","volume":"13","author":"W Li","year":"2022","unstructured":"Li W, et al. Janus kinase inhibitors in the treatment of type I interferonopathies: a case series from a single center in China. Front Immunol. 2022;13:825367.","journal-title":"Front Immunol"},{"key":"1207_CR178","doi-asserted-by":"publisher","first-page":"1615075","DOI":"10.3389\/fimmu.2025.1615075","volume":"16","author":"Y Chen","year":"2025","unstructured":"Chen Y, et al. Response to two Janus kinase inhibitors in a boy with SAVI during 2-year follow-up: case report and literature review. Front Immunol. 2025;16:1615075.","journal-title":"Front Immunol"},{"issue":"2","key":"1207_CR179","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1136\/annrheumdis-2016-209841","volume":"76","author":"N Konig","year":"2017","unstructured":"Konig N, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017;76(2):468\u201372.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1207_CR180","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12969-020-00490-1","volume":"19","author":"S Zhang","year":"2021","unstructured":"Zhang S, et al. Type I interferonopathies with novel compound heterozygous TREX1 mutations in two siblings with different symptoms responded to Tofacitinib. Pediatr Rheumatol Online J. 2021;19(1):1.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"5","key":"1207_CR181","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.jaip.2024.02.013","volume":"12","author":"MA Doroudchi","year":"2024","unstructured":"Doroudchi MA, et al. Anifrolumab to treat a Monogenic interferonopathy. J Allergy Clin Immunol Pract. 2024;12(5):1374\u2013e13761.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1207_CR182","unstructured":"Alehashemi SB, Shakoory A, Almeida de Jesus B, Park A, Uss S, Robles K, Palmblad M, Horne K, Brodin A, Akoghlanian P, Abraham S, Mustillo R, Barillas-Arias P, Heras L, Wampler A, Muskardin T, Lawrence M, Mannem H, Nolan B, Canna S, Reinhardt A, Binstadt B, Goldbach-Mansky R. Anifrolumab normalizes the type I interferon signature in a cohort of patients with type I interferonopathies. Arthritis Rheumatol, 2023. 75 (suppl 9)."},{"issue":"1","key":"1207_CR183","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10875-024-01826-2","volume":"45","author":"G Kretzschmar","year":"2024","unstructured":"Kretzschmar G, et al. Normalized interferon signatures and clinical improvements by IFNAR1 blocking antibody (Anifrolumab) in patients with type I interferonopathies. J Clin Immunol. 2024;45(1):31.","journal-title":"J Clin Immunol"},{"issue":"8","key":"1207_CR184","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/art.43145","volume":"77","author":"S Alehashemi","year":"2025","unstructured":"Alehashemi S, et al. Sustained interferon signature suppression with anifrolumab in a patient with STING-Associated vasculopathy with onset in infancy refractory to JAK inhibitor and Dazukibart therapy. Arthritis Rheumatol. 2025;77(8):1087\u201391.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"1207_CR185","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/dmcn.16199","volume":"67","author":"YJ Crow","year":"2025","unstructured":"Crow YJ, et al. Reverse transcriptase inhibitors in Aicardi-Goutieres syndrome: A crossover clinical trial. Dev Med Child Neurol. 2025;67(6):750\u20137.","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"1207_CR186","first-page":"192","volume":"38","author":"S Sharma","year":"1986","unstructured":"Sharma S, et al. Cross-sectional echocardiography in recognition of left ventricular aneurysm following closed mitral valvotomy. Indian Heart J. 1986;38(3):192\u20134.","journal-title":"Indian Heart J"},{"issue":"2","key":"1207_CR187","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.jaci.2021.03.010","volume":"148","author":"S Kataoka","year":"2021","unstructured":"Kataoka S, et al. Successful treatment of a novel type I interferonopathy due to a de Novo PSMB9 gene mutation with a Janus kinase inhibitor. J Allergy Clin Immunol. 2021;148(2):639\u201344.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1207_CR188","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.jaci.2021.07.039","volume":"149","author":"D Verhoeven","year":"2022","unstructured":"Verhoeven D, et al. Hematopoietic stem cell transplantation in a patient with proteasome-associated autoinflammatory syndrome (PRAAS). J Allergy Clin Immunol. 2022;149(3):1120\u2013e11278.","journal-title":"J Allergy Clin Immunol"},{"issue":"19","key":"1207_CR189","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1182\/blood.2021011005","volume":"138","author":"C Martinez","year":"2021","unstructured":"Martinez C, et al. HSCT corrects primary immunodeficiency and immune dysregulation in patients with POMP-related autoinflammatory disease. Blood. 2021;138(19):1896\u2013901.","journal-title":"Blood"},{"issue":"7","key":"1207_CR190","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1007\/s10875-021-01067-7","volume":"41","author":"A Meinhardt","year":"2021","unstructured":"Meinhardt A, et al. Curative treatment of POMP-Related autoinflammation and immune dysregulation (PRAID) by hematopoietic stem cell transplantation. J Clin Immunol. 2021;41(7):1664\u20137.","journal-title":"J Clin Immunol"},{"issue":"4","key":"1207_CR191","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1172\/JCI129301","volume":"130","author":"AA de Jesus","year":"2020","unstructured":"de Jesus AA, et al. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. J Clin Invest. 2020;130(4):1669\u201382.","journal-title":"J Clin Invest"},{"key":"1207_CR192","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2110190118","author":"AJ Russell","year":"2021","unstructured":"Russell AJ, et al. SAMD9L autoinflammatory or ataxia pancytopenia disease mutations activate cell-autonomous translational repression. Proc Natl Acad Sci U S A. 2021. https:\/\/doi.org\/10.1073\/pnas.2110190118.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1207_CR193","doi-asserted-by":"publisher","first-page":"e13711","DOI":"10.1111\/pai.13711","volume":"33","author":"R Papa","year":"2022","unstructured":"Papa R, et al. Progression of non-hematologic manifestations in SAMD9L-associated autoinflammatory disease (SAAD) after hematopoietic stem cell transplantation. Pediatr Allergy Immunol. 2022;33(1):e13711.","journal-title":"Pediatr Allergy Immunol"},{"issue":"1","key":"1207_CR194","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10875-024-01819-1","volume":"45","author":"H Buso","year":"2024","unstructured":"Buso H, et al. Hematopoietic stem cell transplantation for C1q deficiency: a study on behalf of the EBMT inborn errors working party. J Clin Immunol. 2024;45(1):35.","journal-title":"J Clin Immunol"},{"issue":"1","key":"1207_CR195","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jaci.2018.04.032","volume":"143","author":"T Okano","year":"2019","unstructured":"Okano T, et al. Hematopoietic stem cell transplantation for progressive combined immunodeficiency and lymphoproliferation in patients with activated phosphatidylinositol-3-OH kinase delta syndrome type 1. J Allergy Clin Immunol. 2019;143(1):266\u201375.","journal-title":"J Allergy Clin Immunol"},{"key":"1207_CR196","doi-asserted-by":"crossref","unstructured":"Pearson DM, Wenzel E, Furie J, Dall\u2019Era R, Sanchez-Guerrero M, Roy J, Goodson S, G\u00fchring S, Moreau H, Werth F. V.P., Randomized, placebo-controlled phase ii study of enpatoran, a small molecule toll-like receptor 7\/8 inhibitor, in cutaneous lupus erythematosus: results from cohort A. The Journal of Rheumatology, 2025. May 2025, 52 (Suppl 1) 11.","DOI":"10.3899\/jrheum.2025-0390.O010"},{"key":"1207_CR197","doi-asserted-by":"crossref","unstructured":"Morand EDE, Sanchez-Guerrero M, Pearson J, Werth D, Wenzel VP, Roy J, Kleinmond S, Fernandez-Ruiz C, Klopp-Schulze R, G\u00fchring L, Moreau H, Furie F. R.A., LB0004 randomised, placebo-controlled phase ii study of oral enpatoran, a first-in-class toll-like receptor 7\/8 inhibitor, in systemic lupus erythematosus. Ann Rheum Dis, 2025. 84, Supplement 1316-317June 2025.","DOI":"10.1016\/j.ard.2025.05.391"},{"key":"1207_CR198","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230263","author":"JS Tilstra","year":"2023","unstructured":"Tilstra JS, et al. B cell-intrinsic Myd88 regulates disease progression in murine lupus. J Exp Med. 2023. https:\/\/doi.org\/10.1084\/jem.20230263.","journal-title":"J Exp Med"},{"key":"1207_CR199","doi-asserted-by":"publisher","first-page":"106648","DOI":"10.1016\/j.intimp.2020.106648","volume":"85","author":"Z Zou","year":"2020","unstructured":"Zou Z, et al. TJ-M2010-5, a novel MyD88 inhibitor, corrects R848-induced lupus-like immune disorders of B cells in vitro. Int Immunopharmacol. 2020;85:106648.","journal-title":"Int Immunopharmacol"},{"key":"1207_CR200","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.177003","author":"PR Stabach","year":"2024","unstructured":"Stabach PR, et al. A dual-acting DNASE1\/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models. JCI Insight. 2024. https:\/\/doi.org\/10.1172\/jci.insight.177003.","journal-title":"JCI Insight"},{"issue":"1","key":"1207_CR201","doi-asserted-by":"publisher","first-page":"5695","DOI":"10.1038\/s41467-025-60632-5","volume":"16","author":"T Xie","year":"2025","unstructured":"Xie T, et al. Orthosteric STING inhibition elucidates molecular correction of SAVI STING. Nat Commun. 2025;16(1):5695.","journal-title":"Nat Commun"},{"issue":"37","key":"1207_CR202","doi-asserted-by":"publisher","first-page":"20273","DOI":"10.1021\/jacs.3c03637","volume":"145","author":"L Barasa","year":"2023","unstructured":"Barasa L, et al. Development of LB244, an irreversible STING antagonist. J Am Chem Soc. 2023;145(37):20273\u201388.","journal-title":"J Am Chem Soc"},{"issue":"9","key":"1207_CR203","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41577-021-00524-z","volume":"21","author":"A Decout","year":"2021","unstructured":"Decout A, et al. The cGAS-STING pathway as a therapeutic target in inflammatory diseases. Nat Rev Immunol. 2021;21(9):548\u201369.","journal-title":"Nat Rev Immunol"},{"key":"1207_CR204","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201045","author":"Z Deng","year":"2020","unstructured":"Deng Z, et al. A defect in COPI-mediated transport of STING causes immune dysregulation in COPA syndrome. J Exp Med. 2020. https:\/\/doi.org\/10.1084\/jem.20201045.","journal-title":"J Exp Med"},{"issue":"10","key":"1207_CR205","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1136\/annrheumdis-2018-212988","volume":"77","author":"Y Kato","year":"2018","unstructured":"Kato Y, et al. Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus. Ann Rheum Dis. 2018;77(10):1507\u201315.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1207_CR206","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/acr.23343","volume":"70","author":"Z Yu","year":"2018","unstructured":"Yu Z, et al. Implementation of Treat-to-Target for rheumatoid arthritis in the US: analysis of baseline data from a randomized controlled trial. Arthritis Care Res (Hoboken). 2018;70(5):801\u20136.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"1207_CR207","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","volume":"73","author":"RF van Vollenhoven","year":"2014","unstructured":"van Vollenhoven RF, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958\u201367.","journal-title":"Ann Rheum Dis"},{"key":"1207_CR208","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000516","author":"J Mucke","year":"2021","unstructured":"Mucke J, et al. LUPUS-BEST-treat-to-target in systemic lupus erythematosus: study protocol for a three-armed cluster-randomised trial. Lupus Sci Med. 2021. https:\/\/doi.org\/10.1136\/lupus-2021-000516.","journal-title":"Lupus Sci Med"},{"key":"1207_CR209","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223328","author":"EMD Smith","year":"2023","unstructured":"Smith EMD, et al. Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to-consider from an international task force. Ann Rheum Dis. 2023. https:\/\/doi.org\/10.1136\/ard-2022-223328.","journal-title":"Ann Rheum Dis"},{"key":"1207_CR210","doi-asserted-by":"publisher","first-page":"109296","DOI":"10.1016\/j.clim.2023.109296","volume":"250","author":"EMD Smith","year":"2023","unstructured":"Smith EMD, et al. PReS-endorsed international childhood lupus T2T task force definition of childhood lupus low disease activity state (cLLDAS). Clin Immunol. 2023;250:109296.","journal-title":"Clin Immunol"},{"key":"1207_CR211","doi-asserted-by":"publisher","first-page":"110214","DOI":"10.1016\/j.clim.2024.110214","volume":"263","author":"EMD Smith","year":"2024","unstructured":"Smith EMD, et al. Defining remission in childhood-onset lupus: PReS-endorsed consensus definitions by an international task force. Clin Immunol. 2024;263:110214.","journal-title":"Clin Immunol"},{"key":"1207_CR212","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf057","author":"C Sarker","year":"2025","unstructured":"Sarker C, et al. Validation of childhood lupus specific targets: ensuring accurate assessment of disease control in younger, lighter paediatric patients. Rheumatology (Oxford). 2025. https:\/\/doi.org\/10.1093\/rheumatology\/keaf057.","journal-title":"Rheumatology (Oxford)"},{"key":"1207_CR213","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000884","author":"EM Cody","year":"2023","unstructured":"Cody EM, et al. Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE. Lupus Sci Med. 2023. https:\/\/doi.org\/10.1136\/lupus-2022-000884.","journal-title":"Lupus Sci Med"},{"issue":"1","key":"1207_CR214","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/acr.25443","volume":"77","author":"WD Soulsby","year":"2025","unstructured":"Soulsby WD, et al. Racial disparities and achievement of the low lupus disease activity state: A CARRA registry study. Arthritis Care Res (Hoboken). 2025;77(1):38\u201349.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"1207_CR215","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s10067-023-06533-8","volume":"42","author":"K Na Nakorn","year":"2023","unstructured":"Na Nakorn K, et al. Outcomes of achieving lupus low disease activity state and damage accrual in childhood-onset systemic lupus erythematosus. Clin Rheumatol. 2023;42(6):1655\u201364.","journal-title":"Clin Rheumatol"},{"key":"1207_CR216","doi-asserted-by":"publisher","first-page":"1369969","DOI":"10.3389\/fimmu.2024.1369969","volume":"15","author":"XX Yu","year":"2024","unstructured":"Yu XX, et al. Long-term outcomes and predictive factors of achieving low disease activity status in childhood systemic lupus erythematosus: a Chinese bicentric retrospective registered study. Front Immunol. 2024;15:1369969.","journal-title":"Front Immunol"},{"key":"1207_CR217","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000571","author":"MJ Wahadat","year":"2021","unstructured":"Wahadat MJ, et al. LLDAS is an attainable treat-to-target goal in childhood-onset SLE. Lupus Sci Med. 2021. https:\/\/doi.org\/10.1136\/lupus-2021-000571.","journal-title":"Lupus Sci Med"},{"key":"1207_CR218","doi-asserted-by":"publisher","first-page":"110172","DOI":"10.1016\/j.clim.2024.110172","volume":"262","author":"SC Bergkamp","year":"2024","unstructured":"Bergkamp SC, et al. First validation of the childhood lupus low disease activity state (cLLDAS) definition in a real-life longitudinal cSLE cohort. Clin Immunol. 2024;262:110172.","journal-title":"Clin Immunol"},{"issue":"2","key":"1207_CR219","first-page":"75","volume":"20","author":"EMD Smith","year":"2022","unstructured":"Smith EMD. Low disease activity state and clinical remission are achievable targets in JSLE, leading to a significant reduction in severe flare and new damage. Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022). Pediatr Rheumatol. 2022;20(2):75.","journal-title":"Pediatr Rheumatol"},{"key":"1207_CR220","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf142.136","author":"E Nolan","year":"2025","unstructured":"Nolan E, Lloyd O, Smith EMD. P096\u2003transforming childhood lupus care: initial insights from a treat-to-target service development pilot. Rheumatology. 2025. https:\/\/doi.org\/10.1093\/rheumatology\/keaf142.136.","journal-title":"Rheumatology"},{"key":"1207_CR221","doi-asserted-by":"crossref","unstructured":"Proceedings of the 31st European paediatric rheumatology congress: part 2. Pediatric Rheumatology, 2024. 22(2): p. 83.","DOI":"10.1186\/s12969-024-01005-y"},{"issue":"10","key":"1207_CR222","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1007\/s10067-024-07101-4","volume":"43","author":"R Gotch","year":"2024","unstructured":"Gotch R, et al. Active implementation of low disease activity state as a treatment endpoint in childhood-onset systemic lupus erythematosus in routine practice is both feasible and associated with better outcomes. Clin Rheumatol. 2024;43(10):3231\u20138.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"1207_CR223","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1093\/rheumatology\/keac698","volume":"62","author":"MJ Wahadat","year":"2023","unstructured":"Wahadat MJ, et al. Serum IFN\u03b12 levels are associated with disease activity and outperform IFN-I gene signature in a longitudinal childhood-onset SLE cohort. Rheumatology (Oxford). 2023;62(8):2872\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"1207_CR224","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae643","author":"V Natoli","year":"2024","unstructured":"Natoli V, et al. Elevated serum interferon-\u03b12 associates with activity and flare risk in Juvenile-onset Systemic Lupus Erythematosus. Rheumatology (Oxford). 2024. https:\/\/doi.org\/10.1093\/rheumatology\/keae643.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-025-01207-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-025-01207-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-025-01207-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:02:40Z","timestamp":1770750160000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-025-01207-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":224,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1207"],"URL":"https:\/\/doi.org\/10.1007\/s11926-025-01207-7","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"42"}}